TCI 2013 BioBasque and the Basque BioCluster
Upcoming SlideShare
Loading in...5
×
 

TCI 2013 BioBasque and the Basque BioCluster

on

  • 212 views

By Cristina Oyón, SPRI - Basque Government, presented at the 16th TCI Global Conference, Kolding 2013.

By Cristina Oyón, SPRI - Basque Government, presented at the 16th TCI Global Conference, Kolding 2013.

Statistics

Views

Total Views
212
Views on SlideShare
212
Embed Views
0

Actions

Likes
0
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

TCI 2013 BioBasque and the Basque BioCluster TCI 2013 BioBasque and the Basque BioCluster Presentation Transcript

  • BioBasque and the Basque BioCluster Cristina Oyón Breakout Session: Clusters and smart specialisation strategies: design and implementation 5 September 2013
  • From the different theoretical ways of smart diversification, could the radical foundation of a science based new industrial activity be a sound lever for productive transformation? Source: The Basque Country Competitiveness Report, 2013 - Orkestra The Question
  • The BioRegion
  • The Strategy • First strategy specifically designed (2001-2002) to promote life sciences in Spain • Aim: to develop a new business sector in the Basque Country reated to biosciences • Integrated approach built around three axis: knowledge generation, business development, dynamisation • Mission: to establish a biocluster capable of competing internationall • Cuantitative objectives: 40 new companies, 3.000 new jobs • Chosen as RegioStars 2011 Awards (EU) finalist, among 66 initiatives from 18 countries, awards to most innovative regional projects which have received funding from the EU regional/ cohesion policy
  • The Ecosystem
  • The Research Subsystem Micro-nano-bio convergence
  • The Research Subsystem The Molecular Imaging Facility
  • The Health Subsystem
  • The Health Subsystem DEMOTEK: medical devices effectiveness demonstration unit
  • The Innovation Support Subsystem
  • The Technology Transfer Process
  • The Business Evolution now 2001
  • The Government Support Source: The Basque Country Competitiveness Report, 2013 - Orkestra
  • The Budget Rough figures of public investment in 2012 Knowledge generation ~20 M€ Sector dynamisation ~0,5 M€ Business development ~5 M€
  • The Outcome
  • 18 Service Provision Diagnostics Therapeutics Other Antigens, antibodies one-stop shop Early drug discovery in-vivo Food, environmental safetyDrug development services Drug screening & analysis Clean labs, bio-safety Engineers and consultants agri-food Bromatology lab Drug production support Ophthalmological sanitary products Polymeric dispersion µ-beads Bio-software systems Natural chem. fungicides (crops) Cell-based assays (drug discovery) Metabolomic Dx Vaccines, allergology Drug development (CNS) Regenerative medicine Full-cycle Pharma Tissue engineering, cell therapy Biotech cosmetics Nanomedicines (biocompatible nanoparticles) Drug development, distribution Non-invasive Dx (ophthalmology ) Genetic Dx methods Genomic IVD tests In-vitro Dx tests Dx & Tp animal health The Outcome
  • The Outcome BioBasque is recognized as a BioRegion at national and international scale. We are the 4th community in Spain regarding nr of biotechs, accounting for the 9%, well above the 6% of Spanish GDP that supposes the Basque economy. In 2007-2011 the nr of biotechs has been multiplied by 1,4. The sector employs directly 1.600 persons in R&D, representing 5,8% of total employment in R&D. The R&D personnel accounts for the 50% of total employment The sector invoices more than 300 M€. 57% of biotechs have increased its invoicing in the period 2007-2011. 31% have maintained it. 60% of biotechs are less than 10 years old. 90% of them are internationalized
  • The Future TRANSVERSAL CAPACITIES • Biosciences • Nanosciences • Advanced manufacturing MARKETS • Movility & Transport • Digital World • Science Industry • Ageing / Health • Energy Bio-Nano Sciences Smart Manufacturing Energy EXISTING PRIORIZITATION (PCTI 2015) REFLECTION PROCESS META PRIORITIES REFLECTION PROCESS PILOT PROJECTS Source: The Basque Country Competitiveness Report, 2013 - Orkestra
  • Cristina Oyón Head of Strategic Initiatives, SPRI cristina@spri.es biobasque@spri.es www.biobasque.org